Literature DB >> 2468964

N-acetylcysteine modifies the acute effects of isosorbide-5-mononitrate in angina pectoris patients evaluated by exercise testing.

J H Svendsen1, K Klarlund, J Aldershvile, S Waldorff.   

Abstract

Nitrates are well established in the treatment of angina pectoris and the presence of sulfhydryl groups seems to be fundamental to nitrate-induced vasodilatation. The present study was performed to elucidate if large oral doses of N-acetylcysteine (NAC, 2,400 mg X 2), a donor of sulfhydryl groups, given together with a single oral dose of the long-acting nitrate, isosorbide-5-mononitrate (5-ISMN, 60 mg), would modify the nitrate effect evaluated by exercise testing before and after additional sublingual doses of nitroglycerin (NTG). Ten patients with angina pectoris and angiographically proven significant coronary artery disease were included. All patients received a baseline therapy with beta blockers. None of the patients had developed nitrate tolerance at inclusion. NAC/5-ISMN treatment significantly prolonged the total exercise time as compared with placebo/5-ISMN (7.7 +/- 2.1 min vs. 6.8 +/- 1.7 min, p less than 0.05). This increase was of such magnitude that no further effect was obtained after additional NTG doses. This study demonstrated that increased availability of sulfhydryl groups can increase the exercise capacity in angina pectoris patients treated with 5-ISMN without nitrate tolerance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2468964     DOI: 10.1097/00005344-198902000-00022

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  2 in total

1.  Nitroglycerin relaxes coronary artery of the pig with no change in glutathione content or glutathione S-transferase activity.

Authors:  M Sakanashi; T Matsuzaki; Y Aniya
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

Review 2.  N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency.

Authors:  Kondala R Atkuri; John J Mantovani; Leonard A Herzenberg; Leonore A Herzenberg
Journal:  Curr Opin Pharmacol       Date:  2007-06-29       Impact factor: 5.547

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.